NICE says drug to treat Batten disease cannot be recommended for NHS use because company is unable to address concerns about long-term effectiveness
NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.
Latest news headlines
People showing erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed without the need for blood tests, NICE says in new guidance.
12 February 2019
NICE and Public Health England publish new antibiotic prescribing guidance for patients with suspected pneumonia
These two guidelines set out an antimicrobial prescribing strategy that aims to optimise antibiotic use and reduce antibiotic resistance.
12 February 2019
NICE is updating its guideline on Alcohol interventions in secondary and further education.
08 February 2019
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
NICE and the Canadian Agency for Drugs and Technology in Health (CADTH) have launched a new collaboration to offer parallel scientific advice to the life sciences industry.
06 February 2019
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the Cancer Drugs Fund.
01 February 2019
NICE has announced a collaboration with the body which represents life sciences organisations in the UK.
29 January 2019